ClinicalTrials.gg
Active, not recruitingNCT02650401STARTRK-NGUpdated Sep 23, 2026

Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options

A Phase 1/2 interventional study of Entrectinib in Solid Tumors and CNS Tumors, sponsored by Hoffmann-La Roche. Active, not recruiting at 26 sites in 9 countries. Open to participants aged 0 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-09-23.

Sponsored by Hoffmann-La Roche · Phase 1/2, Interventional, and Treatment

How we know · 16 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
69
Allocation
Non-randomized
Ages
0 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 547 studies in Central Nervous System Neoplasms with a site in United States — 45 open to participants now, 74 under way, 3 of them phase 3. Central Nervous System Neoplasms · United States.

Enrollment
95th of 399
69 · median 31
Started
2016
with 7 others
Phase 1/2
70 of 547
7 open now
Primary completion
2027-06
later than 34 of 73 live
Registered
418th of 547
by date

Among the 547 studies in Central Nervous System Neoplasms with a site in United States, this one is the 95th largest by enrollment of the 399 interventional ones that give a count, is one of 8 that started in 2016, is one of 70 in phase 1/2, reaches primary completion later than 34 of the 73 other live ones, and was the 418th registered.

Central Nervous System Neoplasms

699 studies on the registry are indexed under Central Nervous System Neoplasms; 65 are open to participants now.

Browse Central Nervous System Neoplasms studies →

Open to participants now

45 of the 547 studies in Central Nervous System Neoplasms with a site in United States are open now. Recruiting first, the newest first:

40 more — sign in →

All 45 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 56 Central Nervous System Neoplasms studies recruiting now, 34 (61%) set no upper age limit and 19 (34%) stop at 75 or younger; 34 take children under 18; 6 take healthy volunteers.

This study: 0 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 547 studies in Central Nervous System Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is an open-label, Phase 1/2 multicenter dose escalation study in pediatric patients with relapsed or refractory extracranial solid tumors (Phase 1), with additional expansion cohorts (Phase 2) in patients with primary brain tumors harboring NTRK1/2/3 or ROS1 gene fusions, and extracranial solid tumors harboring NTRK1/2/3 or ROS1 gene fusions.

03

Conditions studied

  • Solid Tumors
  • CNS Tumors

Keywords

  • TRK
  • Tyrosine kinase
  • NTRK
  • NTRK1
  • NTRK2
  • NTRK3
  • ROS1
  • ALK
  • Pediatric
  • Relapsed
  • Refractory
  • Solid Tumor
  • Metastatic Cancer
  • Gene rearrangement
  • Neuroblastoma
  • Infantile fibrosarcoma
  • Secretory breast cancer
  • Congenital mesoblastic nephroma
  • Pontine glioma
  • Brain tumors
  • CNS tumors
  • Sarcoma
  • Ewing sarcoma
  • Glial tumors
  • Salivary Gland Cancer (MASC)
  • Papillary thyroid cancer
  • Medulloblastoma
  • Wilms tumor (anaplastic)
04

Who can participate

Ages eligible
0 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Disease status:

    • Phase 1 portion (closed): Participants must have measurable or evaluable disease, as defined by v1.1
    • Phase 2 portion:

      • Part B: Participants must have measurable or evaluable disease, as defined by RANO
      • Part C (closed): Participants must have measurable or evaluable disease, as defined by RECIST v1.1 ± Curie Scale
      • Part D: Participants must have measurable or evaluable disease, as defined by RECIST v1.1
      • Part E (closed): Participants must have measurable or evaluable disease, as defined by RECIST v1.1 ± Curie Scale or RANO
  2. Tumor type:

    • Phase 1 portion:

      * Part A: extracranial solid tumors

    • Phase 2 portion

      • Part B: Primary brain tumors with NTRK1/2/3 or ROS1 gene fusions; gene fusions are defined as those predicted to translate into a fusion protein with a functional TRKA/B/C or ROS1 kinase domain, without a concomitant second oncodriver as determined by a nucleic acid-based diagnostic testing method
      • Part D: Extracranial solid tumors (including NB) with NTRK1/2/3 or ROS1 gene fusions; gene fusions are defined as those predicted to translate into a fusion protein with a functional TRKA/B/C or ROS1 kinase domain, without a concomitant second oncodriver as determined by a nucleic acid-based diagnostic testing method
  3. Histologic/molecular diagnosis of at diagnosis or the time of relapse
  4. from diagnosis or, preferably, at relapse
  5. Performance status: Lansky or score ≥ 60% and minimum of at least 4 weeks
  6. Prior therapy: Participants must have a disease that is locally advanced, , or where surgical resection is likely to result in severe morbidity, and who have no satisfactory treatment options for solid tumors and primary CNS tumors that are neurotrophic tyrosine receptor kinase (NTRK) or ROS1 fusion-positive
  7. Participants must have recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to enrollment
  8. Adequate organ and neurologic function
  9. Females of must have a negative serum pregnancy test during screening and be neither breastfeeding nor intending to become pregnant during study participation. Agreement to remain abstinent or use use combined methods prior to study entry, for the duration of study participation and in the following 90 days after discontinuation of study treatment.
  10. For male participants with a female partner of childbearing potential or a pregnant female partner: Agreement to remain abstinent or use a condom during the treatment period and for at least 3 months after the last dose of study drug

Exclusion criteria

Exclusion Criteria:

  1. Receiving other experimental therapy
  2. Known congenital long syndrome
  3. History of recent (3 months) symptomatic congestive heart failure or ≤50% at screening
  4. Known active infections
  5. Familial or personal history of congenital bone disorders, bone metabolism alterations or osteopenia
  6. Receiving Enzyme Inducing Antiepileptic Drugs (EIAEDs) within 14 days of first dose.
  7. Prior treatment with approved or TRK or ROS1 inhibitors
  8. Known to entrectinib or any of the other of the investigational medicinal product
  9. Patients with NB with bone marrow space-only disease
  10. Incomplete recovery from acute effects of any surgery prior to treatment.
  11. Active gastrointestinal disease or other malabsorption syndromes that would impact drug absorption.
  12. Other severe acute or chronic medical or psychiatric condition or lab abnormality that may increase the risk associated with study participation, drug administration or may interfere with the interpretation of study results.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
69 participants (actual)

Study arms

  • Active comparator
    Extracranial solid tumors harboring NTRK1/2/3,

    Arm closed for further enrollment ROS1, ALK non-gene fusion molecular alterations Oral entrectinib (RXDX-101)

    Drug: Entrectinib

  • Active comparator
    CNS tumors harboring- NTRK1/2/3, ROS1, ALK

    Arm closed for further enrollment molecular alterations, including gene fusions Oral entrectinib (RXDX-101)

    Drug: Entrectinib

  • Active comparator
    Neuroblastoma

    Arm closed for further enrollment Oral entrectinib (RXDX-101)

    Drug: Entrectinib

  • Active comparator
    Non-neuroblastoma, extracranial solid tumors

    Arm closed for further enrollment harboring - NTRK1/2/3, ROS1, ALK gene fusions Oral entrectinib (RXDX-101)

    Drug: Entrectinib

  • Active comparator
    Any participant unable to swallow capsules

    Arm closed for further enrollment Any participant who otherwise meet all other eligibility criteria Oral entrectinib (RXDX-101)

    Drug: Entrectinib

  • Active comparator
    Expansion: CNS tumors harboring NTRK1/2/3, ROS1

    gene fusions Oral entrectinib (RXDX-101)

    Drug: Entrectinib

  • Active comparator
    Expansion: Extracranial solid tumors harboring NTRK1/2/3, ROS1

    NTRK 1,2,3 and ROS1 fusions Oral entrectinib (RXDX-101)

    Drug: Entrectinib

Interventions

  • TRKA/B/C, ROS1, and ALK inhibitor

    Also known as: RXDX-101

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (MTD)

    Assessed by National Cancer Institute Common Terminology for Adverse Events Criteria (NCI CTCAE v4.03)

    Time frame: Approximately 6 months

  2. Recommended Phase 2 Dose (RP2D) of F1 Formulation In Pediatric Participants Able To Swallow Intact Capsules

    Assessed by NCI CTCAE v4.03

    Time frame: Approximately 6 months

  3. Recommended Phase 2 Dose (RP2D) of F06 Formulation In Pediatric Participants Able To Swallow Intact Capsules

    Assessed by NCI CTCAE v4.03

    Time frame: Approximately 6 months

  4. Recommended Phase 2 Dose (RP2D) of F06 Formulation In Pediatric In Participants Dosed Via Feeding Tube (Nasogastric Tube Or Gastric Tube)

    Assessed by NCI CTCAE v4.03

    Time frame: Approximately 6 months

  5. Recommended Phase 2 Dose (RP2D) Of Minitablets/F15 Formulation In Pediatric Participants Unable To Swallow Intact Capsules

    Assessed by NCI CTCAE v4.03

    Time frame: Approximately 6 months

  6. Cohort B: Objective Response Rate (ORR)

    Assessed by RANO per the BICR

    Time frame: Approximately 6 months

  7. Cohort D: ORR

    Assessed by RECIST v1.1 per the BICR

    Time frame: Approximately 6 months

Secondary outcomes

  1. Safety and Tolerability - AE, ECG and Labs assessed by NCI CTCAE v4.03

    AE, ECG and Labs assessed by NCI CTCAE v4.03

    Time frame: Approximately 24 months

  2. Maximum observed plasma drug concentration (Cmax) using F1 Formulation

    Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

    Time frame: Approximately 24 months

  3. Maximum observed plasma drug concentration (Cmax) using F06 Formulation given intact

    Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

    Time frame: Approximately 24 months

  4. Maximum observed plasma drug concentration (Cmax) using F06 Formulation administered via feeding tube

    Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

    Time frame: Approximately 24 months

  5. Maximum observed plasma drug concentration (Cmax) using minitablets/F15

    Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

    Time frame: Approximately 24 months

  6. Time to Cmax, by inspection (Tmax) using F1 Formulation

    Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

    Time frame: Approximately 24 months

  7. Time to Cmax, by inspection (Tmax) using F06 Formulation given intact

    Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

    Time frame: Approximately 24 months

  8. Time to Cmax, by inspection (Tmax) using F06 Formulation administered via feeding tube

    Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

    Time frame: Approximately 24 months

  9. Time to Cmax, by inspection (Tmax) using minitablets/F15

    Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

    Time frame: Approximately 24 months

  10. AUC at steady state (AUCss) using F1 Formulation

    Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

    Time frame: Approximately 24 months

  11. AUC at steady state (AUCss) using F06 Formulation given intact

    Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

    Time frame: Approximately 24 months

  12. AUC at steady state (AUCss) using F06 Formulation administered via feeding tube

    Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

    Time frame: Approximately 24 months

  13. AUC at steady state (AUCss) using minitablets/F15

    Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

    Time frame: Approximately 24 months

  14. Terminal half life (t½) using F1 Formulation

    Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

    Time frame: Approximately 24 months

  15. Terminal half life (t½) using F06 Formulation given intact

    Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

    Time frame: Approximately 24 months

  16. Terminal half life (t½) using F06 Formulation administered via feeding tube

    Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

    Time frame: Approximately 24 months

  17. Terminal half life (t½) using minitablets/F15

    Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

    Time frame: Approximately 24 months

  18. Area under the drug concentration by time curve (AUC) using F1 Formulation

    Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

    Time frame: Approximately 24 months

  19. Area under the drug concentration by time curve (AUC) using F06 Formulation given intact

    Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

    Time frame: Approximately 24 months

  20. Area under the drug concentration by time curve (AUC) using F06 Formulation administered via feeding tube

    Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

    Time frame: Approximately 24 months

  21. Area under the drug concentration by time curve (AUC) using minitablets/F15

    Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

    Time frame: Approximately 24 months

  22. Cohort A, D, or E: Clinical Benefit Rate (CBR)

    Assessed by RECIST v1.1 per the BICR and investigator

    Time frame: Approximately 6 months

  23. Cohort B or E: CBR

    Assessed by RANO per the BICR and investigator

    Time frame: Approximately 6 months

  24. Cohort C: CBR

    Assessed by the Curie scale per the BICR and investigator

    Time frame: Approximately 6 months

  25. Cohort A, D, or E: Progression-free Survival (PFS)

    Assessed by RECIST v1.1 per the BICR and investigator

    Time frame: Approximately 6 months

  26. Cohort B or E: PFS

    Assessed by RANO per the BICR and investigator

    Time frame: Approximately 6 months

  27. Cohort C: PFS

    Assessed by the Curie scale per the BICR and investigator

    Time frame: Approximately 6 months

  28. Cohort A, D, or E: Overall Survival (OS)

    Assessed by RECIST v1.1

    Time frame: Approximately 6 months

  29. Cohort B or E: OS

    Assessed by RANO

    Time frame: Approximately 6 months

  30. Cohort A, D, or E: ORR

    Assessed by RECIST v1.1 per the BICR and investigator

    Time frame: Approximately 6 months

  31. Cohort B or E: ORR

    Assessed by RANO per the BICR and investigator

    Time frame: Approximately 6 months

  32. Cohort C: ORR

    Assessed by the Curie scale per the BICR and investigator

    Time frame: Approximately 6 months

  33. Cohort A, D, or E: Time to response (TTR)

    Assessed by RECIST v1.1 per the BICR and investigator

    Time frame: Approximately 6 months

  34. Cohort B or E: TTR

    Assessed by RANO per the BICR and investigator

    Time frame: Approximately 6 months

  35. Cohort C: TTR

    Assessed by the Curie scale per the BICR and investigator

    Time frame: Approximately 6 months

  36. Cohort A, D, or E: Duration of Response (DOR)

    Assessed by RECIST v1.1 per the BICR and investigator

    Time frame: Approximately 6 months

  37. Cohort B or E: DOR

    Assessed by RANO per the BICR and investigator

    Time frame: Approximately 6 months

  38. Cohort C: DOR

    Assessed by the Curie scale per the BICR and investigator

    Time frame: Approximately 6 months

  39. Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): ORR

    Assessed by RANO per the investigator

    Time frame: Approximately 6 months

  40. Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort D or E): ORR

    Assessed by RECIST v1.1 per the investigator

    Time frame: Approximately 6 months

  41. Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort A, D, or E): ORR

    Assessed by RECIST v1.1 per the BICR and investigator

    Time frame: Approximately 6 months

  42. Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort B or E): ORR

    Assessed by RANO per the BICR and investigator

    Time frame: Approximately 6 months

  43. Phase 1/2 Participants with ROS1 gene fusions (Cohort A, D, or E): ORR

    Assessed by RECIST v1.1 per the BICR and investigator

    Time frame: Approximately 6 months

  44. Phase 1/2 Participants with ROS1 gene fusions (Cohort B or E): ORR

    Assessed by RANO per the BICR and investigator

    Time frame: Approximately 6 months

  45. Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort A, D, or E): ORR

    Assessed by RECIST v1.1 per the BICR and investigator

    Time frame: Approximately 6 months

  46. Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): ORR

    Assessed by RANO per the BICR and investigator

    Time frame: Approximately 6 months

  47. Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): DOR

    Assessed by RANO per the BICR and investigator

    Time frame: Approximately 6 months

  48. Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort D or E): DOR

    Assessed by RECIST v1.1 per the BICR and investigator

    Time frame: Approximately 6 months

  49. Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort A, D, or E): DOR

    Assessed by RECIST v1.1 per the BICR and investigator

    Time frame: Approximately 6 months

  50. Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort B or E): DOR

    Assessed by RANO per the BICR and investigator

    Time frame: Approximately 6 months

  51. Phase 1/2 Participants with ROS1 gene fusions (Cohort A, D, or E): DOR

    Assessed by RECIST v1.1 per the BICR and investigator

    Time frame: Approximately 6 months

  52. Phase 1/2 Participants with ROS1 gene fusions (Cohort B or E): DOR

    Assessed by RANO per the BICR and investigator

    Time frame: Approximately 6 months

  53. Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort A, D, or E): DOR

    Assessed by RECIST v1.1 per the BICR and investigator

    Time frame: Approximately 6 months

  54. Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): DOR

    Assessed by RANO per the BICR and investigator

    Time frame: Approximately 6 months

  55. Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): TTR

    Assessed by RANO per the BICR and investigator

    Time frame: Approximately 6 months

  56. Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort D or E): TTR

    Assessed by RECIST v1.1 per the BICR and investigator

    Time frame: Approximately 6 months

  57. Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort A, D, or E): TTR

    Assessed by RECIST v1.1 per the BICR and investigator

    Time frame: Approximately 6 months

  58. Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort B or E): TTR

    Assessed by RANO per the BICR and investigator

    Time frame: Approximately 6 months

  59. Phase 1/2 Participants with ROS1 gene fusions (Cohort A, D, or E): TTR

    Assessed by RECIST v1.1 per the BICR and investigator

    Time frame: Approximately 6 months

  60. Phase 1/2 Participants with ROS1 gene fusions (Cohort B or E): TTR

    Assessed by RANO per the BICR and investigator

    Time frame: Approximately 6 months

  61. Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort A, D, or E): TTR

    Assessed by RECIST v1.1 per the BICR and investigator

    Time frame: Approximately 6 months

  62. Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): TTR

    Assessed by RANO per the BICR and investigator

    Time frame: Approximately 6 months

07

Study locations

26 sites
08

References and documents

Publications

  • Desai AV, Bagchi A, Armstrong AE, van Tilburg CM, Basu EM, Robinson GW, Wang H, Casanova M, Andre N, Campbell-Hewson Q, Wu Y, Cardenas A, Ci B, Ryklansky C, Devlin CE, Meneses-Lorente G, Wulff J, Hutchinson KE, Gajjar A, Fox E. Efficacy and safety of entrectinib in children with extracranial solid or central nervous system (CNS) tumours harbouring NTRK or ROS1 fusions. Eur J Cancer. 2025 May 2;220:115308. doi: 10.1016/j.ejca.2025.115308. Epub 2025 Feb 22. PubMed 40086048 ↗
  • Desai AV, Robinson GW, Gauvain K, Basu EM, Macy ME, Maese L, Whipple NS, Sabnis AJ, Foster JH, Shusterman S, Yoon J, Weiss BD, Abdelbaki MS, Armstrong AE, Cash T, Pratilas CA, Corradini N, Marshall LV, Farid-Kapadia M, Chohan S, Devlin C, Meneses-Lorente G, Cardenas A, Hutchinson KE, Bergthold G, Caron H, Chow Maneval E, Gajjar A, Fox E. Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG). Neuro Oncol. 2022 Oct 3;24(10):1776-1789. doi: 10.1093/neuonc/noac087. PubMed 35395680 ↗
  • Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, Loong HH, Buchschacher GL Jr, Garrido P, Nieva J, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD; trial investigators. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020 Feb;21(2):271-282. doi: 10.1016/S1470-2045(19)30691-6. Epub 2019 Dec 11. PubMed 31838007 ↗

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2016 (actual). Primary completion is estimated for Jun 2027, 133 months after the start.

Of 35 phase 1/2 interventional studies under Central Nervous System Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 48 and three quarters within 85. This study's planned 133 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2016
First posted
Jan 8, 2016
StartActual
May 3, 2016
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Sep 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02650401
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jan 8, 2016
Start date
May 3, 2016
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Sep 23, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Entrectinib

Start the discussion